

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

**Vosoritide for treating achondroplasia in people 4 months and over
ID6488**

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> BioMarin Pharmaceuticals (vosoritide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Arthritis and Musculoskeletal Alliance Child Growth Foundation Dwarf Sports Association Foundation Exploring Skeletal Dysplasia Together Gene People Genetic Alliance UK Little People UK Restricted Growth Association UK South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors British Association of Paediatric Surgeons British Geriatrics Society British Institute of Musculoskeletal Medicine British Myology Society British Orthopaedic Association British Paediatric and Adolescent Bone Group British Pain Society British Society for Children's Orthopaedic Surgery British Society for Genetic Medicine British Society for Paediatric Endocrinology and Diabetes British Society for Rheumatology British Society of Physical and Rehabilitation Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government NHS Wales Joint Commissioning Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Ascendis Pharma (lonapegsomatropin) Ferring (somatropin) Merck Serono (somatropin) Novo Nordisk (somatropin, somapacitan) Pfizer (somatropin, somatrogon) Sandoz (somatropin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Bone Research Society Chronic Pain Policy Coalition Cochrane Musculoskeletal Group Genomics England MRC Clinical Trials Unit National Institute for Health Research

Provisional stakeholder list for the evaluation of vosoritide for treating achondroplasia in people 4 months and over ID6488. Issue date: March 2025

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Neonatal and Paediatric Pharmacists Group • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association • Chartered Society of Physiotherapy • Royal College of Occupational Therapists • Primary Care Rheumatology and Musculoskeletal Medicine Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust • NHS England • Department of Children's Orthopaedics, University Hospital Southampton NHS Foundation Trust • Department of Endocrinology, University Hospitals Birmingham Foundation Trust • Department of Orthopaedic and Spine Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust • Developmental Disorders Clinic, Manchester Centre for Genomic Medicine, Manchester NHS Foundation Trust • Paediatric Trauma and Orthopaedic Surgery, University Hospitals Bristol NHS Foundation Trust 	<ul style="list-style-type: none"> • Orthopaedic Research UK • Pain Relief Foundation • Society of Back Pain Research • Skeletal Dysplasia Group • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme (NETSCC)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected

Provisional stakeholder list for the evaluation of vosoritide for treating achondroplasia in people 4 months and over ID6488. Issue date: March 2025

characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.